SEC Form 4 · accession 0001209191-18-064320
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher B Prentiss
Officer — Chief Accounting Officer
Period of report
Dec 27, 2018
Accepted (ET)
Dec 28, 2018 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 27, 2018 | A | 12,500 | $0.00 | A | 30,726 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on July 20, 2019 and January 20, 2020 and 50% of the total number of Restricted Stock Units will vest on January 20, 2021, subject to Reporting Person's Continuous Service as of each such date.